AMDL Presentation of China Success Story from Rodman & Renshaw Annual Healthcare Conference Available at WallStreetReporter.com
November 23 2007 - 1:12AM
PR Newswire (US)
TUSTIN, Calif., Nov. 23 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADLAMEX:-AMEX:News), headquartered in Tustin, California,
with operations in Shenzhen, Jiangxi and Jilin, China, through its
wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an
international biopharma company that engages in the development,
manufacture and marketing of proprietary pharmaceutical and
diagnostic products. The Company announced today that the recent
presentation by its CEO, Gary Dreher, at the prestigious 9th Annual
Healthcare Conference sponsored by the full-service investment
bank, Rodman & Renshaw, and its life science division, Acumen
BioFin,(TM) is now available at WallStreetRepoter.com. The link to
listen to the presentation is at
http://www.wallstreetreporter.com/page.php?page=view_videos&id=134
Mr. Dreher noted that "AMDL recently announced that it had sales of
approximately $5.8 million for the third quarter of 2007 compared
to $2.3 million for the second quarter of 2007 with $0.05 per share
in earnings. AMDL's introduction of new products and increased
distribution channels caused the upturn in revenues and profits.
This marked AMDL's first quarter with positive cash flow and net
earnings. These superior results indicate that we anticipate that
our Chinese subsidiaries will continue to experience strong sales
and gross profit growth that will greatly improve AMDL's combined
operating results." About JPI: Jade Pharmaceutical has access to
the fastest growing pharmaceutical and consumer market in the
world: China. AMDL, through its subsidiary, Jade currently
manufactures large volume injectable fluids, tablets and other
related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. About AMDL: More information about AMDL
and its products can be obtained at http://www.amdl.com/ . Contact:
AMDL, Inc. Paul Knopick AMDL Investor Relations Direct Line:
949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: Paul Knopick, AMDL Investor Relations, Direct Line:
+1-949-707-5365, Voice Mail: +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024